Citations

Clear

6 citation(s) found for "Deshpande, Anagha".

The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer
Cheung, Dillon C , Deshpande, Anagha J, Sandrasegaran, Kumar

Mayo Clinic

The American Surgeon™ | October 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261495994 | PMID 42852719 Get It

Background Sarcopenia is associated with worse outcomes in pancreatic cancer patients, but longitudinal body composition changes during neoadjuvant therapy remain poorly understood. Methods A retrospective review identified patients who underwent pancreatectomy, either upfront or after neoadjuvant therapy, for pancreatic adenocarcinoma between 2011 and 2021. Skeletal muscle area, index, and mean attenuation were calculated from CT images throughout the treatment course to assess sarcopenia. Multivariable generalized linear and logistic regression models were used to assess associations between sarcopenia, neoadjuvant therapy, and postoperative outcomes. Results A total of 72 patients were included: 32 who underwent neoadjuvant therapy and 40 who underwent upfront surgery. Forty-one (57%) patients had sarcopenia at diagnosis (65% upfront surgery vs 47% neoadjuvant, P = 0.154). Post-neoadjuvant therapy, 15.6% developed and 18.8% resolved sarcopenia. Median skeletal muscle mean attenuation increased by 2.4 HU after neoadjuvant therapy ( P = 0.02). Patients receiving neoadjuvant therapy were more likely to undergo nutrition consultation prior to surgery (61% vs 7%, P = 0.003). Neoadjuvant therapy was also associated with higher postoperative albumin levels (β = 0.244; 95% CI 0.041-0.446). Baseline sarcopenia diagnosed by skeletal muscle area was associated with increased postoperative complications (OR 13.696; 95% CI 2.537-73.921), while neoadjuvant therapy did not significantly impact complications (OR 0.384; 95% CI 0.12-1.226). Conclusions Patients who completed neoadjuvant therapy and underwent resection did not have increased rates of sarcopenia and were more likely to receive preoperative nutrition consultation and have higher postoperative albumin levels. The neoadjuvant period may represent an opportunity for sarcopenia assessment, nutritional optimization, and multimodal prehabilitation prior to pancreatectomy.
Bailout Procedures, Downstream Outcomes, and Cost After Robotic vs Laparoscopic Cholecystectomy for Acute Cholecystitis
Cheung, Dillon, Li, Xingjie , Deshpande, Anagha , Lim, Pei‐Wen

Mayo Clinic

Journal of the American College of Surgeons | September 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/xcs.0000000000002206 | PMID 42803467 Get It

Background: Robotic cholecystectomy use is increasing, but comparisons with laparoscopic cholecystectomy have largely excluded bailout procedures, limiting assessment of difficult acute cholecystitis. We compared bailout use, downstream outcomes, and 1-year costs between approaches. Study Design: This retrospective cohort study used Healthcare Cost and Utilization Project databases from New York and Florida (2012–2021) to identify adults undergoing inpatient, unscheduled robotic or laparoscopic cholecystectomy for acute cholecystitis. Bailout included conversion to open, subtotal cholecystectomy, or cholecystostomy tube placement. Multilevel regression evaluated bailout, and postoperative outcomes were assessed through 1 year. Results: Among 384,617 patients, 4% underwent robotic and 96% laparoscopic cholecystectomy. Robotic cholecystectomy had higher bailout rates (1.7% vs 1.4%; adjusted OR 1.38, 95% CI 1.21-1.58), including higher odds of conversion to open (OR 1.61, 95% CI 1.28-2.03) and subtotal cholecystectomy (OR 2.02, 95% CI 1.68-2.43), but lower odds of cholecystostomy tube placement (OR 0.42, 95% CI 0.28-0.62). Bile duct injury rates were similar (1.6% for both; p=0.998). Among 5,448 patients requiring bailout, robotic cholecystectomy was associated with fewer postoperative endoscopic biliary (3.1% vs 7.7%; p=0.007) and surgical interventions (2.3% vs 7.5%; p=0.002). Median 1-year cumulative costs remained higher with robotic cholecystectomy ($29,702 vs $24,483; p=0.002). Conclusions: Robotic cholecystectomy was associated with marginally higher bailout use and similar bile duct injury rates but fewer downstream interventions after bailout. These potential benefits did not offset higher 1-year costs.
Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma
Deshpande, Anagha , Muñoz, Javier , Kurzrock, Razelle

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | March 4, 2024 | Volume: 7 | Issue: 3 | Pages: 201-204

10.36401/jipo-23-47 | PMID 39219994 Get It

ABSTRACT A 62-year-old man presented with a slowly growing, painless lesion on his face. This eventually led to a progressive left-eye vision lesion, and the patient was subsequently diagnosed with advanced basal cell carcinoma (BCC). Of note, BCC involving cranial nerves is extremely rare, making this case unique and important to highlight. Standard treatment options for BCC involve surgery, radiation, or platinum-based chemotherapy. However, targeted therapies such as sonidegib and vismodegib – sonic hedgehog pathway inhibitors – have emerged that have been approved for treating BCC, as have anti-PD1 immunotherapies, such as cemiplimab, with their success likely based on the high tumor mutational burden seen in some of these tumors. Epidermal growth factor receptor (EGFR) inhibitors also serve a role in treating this condition as well. Molecular studies on metastatic/advanced BCC and other rare malignancies may inform treatment therapeutic decisions.
Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1
Deshpande, Anagha , Dabak, Vrushali, Hanbali, Amr , Muñoz, Javier , Kurzrock, Razelle

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | January 12, 2024 | Volume: 7 | Issue: 2 | Pages: 122-125

10.36401/jipo-23-32 | PMID 38721407 Get It

ABSTRACT Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder that primarily causes the growth of tumors along nerves. Additionally, the germline mutations involved in NF1 predispose patients to develop further malignancies. The mainstay initial treatment for these malignancies is surgical removal at diagnosis, although targeted therapies are under evaluation in the relapsed setting. We report a case of malignant peripheral nerve sheath tumor (MPNST), gastrointestinal stromal tumor (GIST), and pheochromocytoma in a patient with NF1 who presented with an infected right shoulder lesion that was confirmed to be spindle cell sarcoma via biopsy. She was treated with antibiotics; however, she rapidly deteriorated and opted for hospice care. NF1 germline mutations increase the risk of patients developing various types of cancer. Recent studies have shown that there is a role for using MEK inhibitors such as selumetinib for treating patients with NF1.
Is YouTube a Good Resource for Laparoscopic Adrenalectomy Education Content?
Orton, Taylor S., Eldredge, Richard S, Hangge, Patrick T., Wasif, Nabil , Stucky, Chee-Chee H, Eldredge, R Scott , Deshpande, Anagha , Stucky, Chee‐Chee , Cronin, Patricia A

Mayo Clinic

Journal of the American College of Surgeons | April 17, 2023 | Volume: 236 | Issue: 5 | Pages: S26-S26

10.1097/01.xcs.0000932468.42395.f5 Get It

Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver
Deshpande, Anagha , Kelemen, Katalin, Dabak, Vrushali, Hanbali, Amr , Muñoz, Javier , Kurzrock, Razelle

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | December 27, 2022 | Volume: 6 | Issue: 1 | Pages: 56-58

10.36401/jipo-22-22 | PMID 36751660 Get It

ABSTRACT Primary splenic or hepatic angiosarcomas are ultra-rare and aggressive malignancies associated with poor prognosis. The mainstay treatments are surgical resection and chemotherapy. We report a case of angiosarcoma in a 50-year-old woman who presented with bruising, fatigue, ecchymosis, and hepatosplenomegaly. She was treated with the multi-kinase inhibitor sunitinib for 4 weeks before developing a splenic hemorrhage and succumbing. Recent studies have demonstrated the clinical benefit of immunotherapies in angiosarcomas. Additionally, sequencing techniques have showcased the diverse molecular aberrations involved in angiosarcomas, which offer opportunities for precision-matched targeted therapies such as inhibitors of the VEGF/VEGFR axis and PI3K/Akt/mTor pathway.